|
Real-time Estimate
Cboe BZX
17:45:05 13/03/2026 GMT
|
5-day change
|
1st Jan Change
|
|
96.24 USD
|
+1.23%
|
 |
-2.19%
|
+20.83%
|
| 01:06pm |
Wall Street Clings to Hope
|  | | 08:43am |
Analyst recommendations: Adobe, Oracle, Dow, Him & Hers, Whirlpool…
| | |
03-04 |
Revolution Medicines Insider Sold Shares Worth $3,644,354, According to a Recent SEC Filing
|
MT
| |
03-03 |
Revolution Medicines, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 09:50 AM
| | |
02-27 |
Revolution's Daraxonrasib has 'Blockbuster' Potential, UBS Says
|
MT
| |
02-27 |
UBS Adjusts Revolution Medicines Price Target to $145 From $71, Maintains Buy Rating
|
MT
| |
02-27 |
Truist Adjusts Price Target on Revolution Medicines to $116 From $99, Maintains Buy Rating
|
MT
| |
02-27 |
Truist Raises Price Target on Revolution Medicines to $116 From $99, Keeps Buy Rating
|
MT
| |
02-26 |
The Bar Just Moved Higher
| | |
02-26 |
Mizuho Trims Price Target on Revolution Medicines to $140 From $143, Keeps Outperform Rating
|
MT
| |
02-26 |
Revolution Medicines, Inc., Q4 2025 Earnings Call, Feb 25, 2026
| | |
02-26 |
Revolution Medicines Inc files for common stock offering of up to $1.0 billion
|
RE
| |
02-25 |
Revolution Medicines Q4 Loss Widens
|
MT
| |
02-25 |
Earnings Flash (RVMD) Revolution Medicines Posts Q4 Loss $1.86, vs. FactSet Est of $1.58 Loss
|
MT
| |
02-25 |
Revolution Medicines : Corporate Presentation (b5f2fd)
|
PU
| |
02-25 |
Revolution Medicines, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
|
CI
| |
02-25 |
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
|
AQ
| |
02-24 |
Revolution Medicines : to Participate in TD Cowen 46th Annual Health Care Conference
|
PU
| |
02-24 |
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
|
AQ
| |
02-18 |
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
|
AQ
| |
02-11 |
Revolution Medicines, Inc. Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026, Feb-11-2026 09:30 AM
| | |
02-04 |
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
|
AQ
| |
01-29 |
Revolution Medicines Says First Patient Dosed in Solid Tumor Trial
|
MT
| |
01-29 |
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
|
CI
| |
01-29 |
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
|
AQ
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
